DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - Generic Drug Details

What are the generic drug sources for dorzolamide hydrochloride; timolol maleate and what is the scope of patent protection?

Dorzolamide hydrochloride; timolol maleate is the generic ingredient in three branded drugs marketed by Thea Pharma, Alembic, Bausch And Lomb, Chartwell Molecular, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Hikma, Ingenus Pharms Llc, Micro Labs, New Heightsrx, Regcon Holdings, Rubicon Research, Sandoz, Somerset, Teva Pharms, and Zambon Spa, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

Sixteen suppliers are listed for this compound.

Summary for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

US Patents:	0
Tradenames:	3
Applicants:	18
NDAs:	22
Finished Product Suppliers / Packagers:	16
Clinical Trials:	9
DailyMed Link:	DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE at DailyMed

Recent Clinical Trials for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Florida	Phase 1
Allergan	Phase 3
Allergan	Phase 4

See all DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE clinical trials

Pharmacology for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Drug Class	Carbonic Anhydrase Inhibitor beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists Carbonic Anhydrase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01EC	Carbonic anhydrase inhibitors
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COSOPT	Ophthalmic Solution	dorzolamide hydrochloride; timolol maleate	2%/0.5%	020869	1	2005-10-11

US Patents and Regulatory Information for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	078704-001	Sep 28, 2009		DISCN	No	No
Rubicon Research	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	078201-001	Oct 28, 2008		DISCN	No	No
Eugia Pharma	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	207630-001	Jul 24, 2018	AT2	RX	No	No
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998	AT1	RX	Yes	Yes

Expired US Patents for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics and Financial Trajectory for DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

Market Overview

Dorzolamide Hydrochloride and Timolol Maleate form a combination drug used primarily to lower intraocular pressure in patients with glaucoma or ocular hypertension. This combination therapy is delivered as an eye drop, marketed under brands such as Cosopt (by Merck & Co.). It competes within a mature segment with other combination formulations and standalone agents.

Market Size and Growth Trends

• The global glaucoma drugs market valued at approximately $5.6 billion in 2022, with expected compound annual growth rate (CAGR) between 4% and 6% through 2027 [1].
• Dorzolamide-Timolol formulations hold roughly 15% to 20% of the overall glaucoma drugs market, indicating strong presence in the topical combination space.
• The adoption rate for fixed-dose combinations (FDCs) like Dorzolamide/Timolol has increased due to improved patient adherence and simplified dosing regimens.

Key Market Drivers

• Rising prevalence of glaucoma: Estimated over 76 million people affected worldwide, projected to reach 112 million by 2040 [2].
• Aging populations: Increased age correlates with higher glaucoma incidence.
• Therapeutic efficacy: Early data shows high intraocular pressure reduction, comparable to other multi-agent formulations.
• Patient compliance: FDCs reduce the necessity for multiple drops, improving adherence.

Competitive Landscape

• Main competitors include Latanoprost-Bimatoprost combinations, Brinzolamide-Timolol, and prostaglandin analogs.
• Patent expirations: The original patents for Cosopt expired around 2016, leading to generics entering the market.
• Market shares split among branded and generic versions. Generic formulations now account for approximately 70-80% of sales in mature markets.

Regulatory and Patent Considerations

• Regulatory approvals uniformly granted across major markets including FDA (U.S.), EMA (EU), and PMDA (Japan).
• Patent protections for the original formulation expired between 2016-2018; current formulations are either off-patent or rely on secondary patents.
• Companies developing new formulations or delivery systems face patent litigation risks but can leverage regulatory pathways for biosimilars or new chemical entities.

Revenue and Market Penetration

• Leading manufacturer Merck's Cosopt recorded revenues approximating $300-$400 million annually in mature markets pre-generic entry.
• Post-patent expiry reductions reflect patent cliff effects, yet market penetration remains high due to brand recognition.

Financial Trajectory

• Market penetration rates stabilize at lower levels post-generic entry; revenue erosion observed.
• Expected CAGR for generic versions aligns with overall glaucoma market growth (~4-6%), but branded product revenues decline faster due to price competition.
• Investment in new formulations or extended-release systems could buffer revenue decline; such innovations are in early R&D stages.

R&D and Pipeline Outlook

• Limited pipeline for this specific combination; focus on delivery advancements (e.g., sustained-release drops).
• Companies exploring adjunctive therapies or new indications (e.g., neuroprotection in glaucoma).

Market Opportunities

• Developing countries exhibit high unmet needs; emerging markets expected to experience higher CAGR, driven by increasing healthcare access.
• Transition to digital health records increases opportunities for adherence tracking and personalized therapy management.
• Entry of biosimilars and generics widens market access but pressures margins for brand owners.

Risks and Challenges

• Patent litigations and regulatory delays.
• Market saturation in mature regions limits growth.
• Price erosion due to generics.
• Competitive emergence of innovative delivery systems.

Key Financial Indicators

Indicator	2022	Projected 2027	Notes
Market Size	~$5.6B globally	~$7.0B	Growth driven by prevalence and adoption
Brand Revenue	~$300-$400M (Cosopt)	Declines post-generic entry	due to patent expiration
Generic Market Share	70-80%	Stable or increasing	commoditization effect

---

Key Takeaways

• Combination therapy of Dorzolamide Hydrochloride and Timolol Maleate holds a significant market share for glaucoma treatment, with revenues impacted heavily by patent expirations.
• The overall glaucoma drugs market is growing steadily, driven by aging populations globally.
• Competitive pressures from generics and new formulations encourage innovation but suppress revenue growth for original branded drugs.
• Opportunities exist in emerging markets and through development of sustained-release delivery systems.
• R&D focus is shifting towards improved adherence and extended efficacy rather than new chemical entities.

FAQs

1. What factors influence the sales of Dorzolamide-Timolol combination drugs?
Market size, patent status, generic competition, prevalence of glaucoma, regulatory approvals, and advances in drug delivery impact sales.

2. How does patent expiry affect the financial outlook for this medication?
Patent expiry typically leads to revenue decline for the original manufacturer due to generic competition, but it may open new market segments and lower prices.

3. Are there ongoing innovations in formulations for this drug combination?
Yes, research is underway in sustained-release eye drops and novel delivery devices; however, no major breakthroughs have yet entered the market.

4. What regions present the highest growth potential?
Emerging markets in Asia, Latin America, and Africa show higher CAGR for glaucoma therapies owing to increasing healthcare access and disease prevalence.

5. How does competition from other classes of glaucoma medications impact this combination drug?
Prostaglandin analogs and neuroprotective agents compete for market share, particularly in regions favoring newer therapies with longer dosing intervals.

---

References

[1] Research and Markets. "Global Glaucoma Drugs Market Size & Share Analysis," 2023.
[2] Tham, Y.C. et al. "Global prevalence of glaucoma and projections of glaucoma burden through 2090," The Ophthalmology Journal, 2014.